At the close of February 27, Corning Oncology Pharmaceuticals-B (09966) closed at HK$6.08, up 22.33%, with a turnover rate of 3.63%, a trading volume of 34.9652 million shares, and a turnover of HK$205 million. The company's stock price has been "seven consecutive positives", rising 99.34% since February 3.

With the help of AI empowerment, the popularity of innovative drugs has not diminished. The Hong Kong Stock Innovative Drug ETF (159567) rose by 2.86% during the intraday session on February 27, and finally closed at 0.95%, with a turnover of 359 million yuan and a turnover rate of over 73%. Since hitting the bottom on January 13, the Hong Kong Stock Innovative Drug ETF has risen by 30.79%.

Hang Seng Index Company recently announced the results of its regular quarterly index adjustments. This coincides with the semi-annual index review of the Hang Seng Composite Index, which will become the main basis for the investment scope of Hong Kong Stock Connect. Among them, Corning Oncology Pharmaceuticals-B was removed from the Hang Seng Composite Index. Huatai Securities said that the company may be removed from the Hong Kong Stock Connect list in March, and CICC's research report did not mention that the company will be removed from the Hong Kong Stock Connect.

Corning Oncology Biopharmaceuticals-B, established in 2015, was listed on the main board of the Hong Kong Stock Exchange on December 12, 2019. It is an investment holding company mainly engaged in the research and development, manufacturing and commercialization of tumor biological agents. In the first half of 2024, the operating income was 174 million yuan, a year-on-year increase of 27.18%, and the net profit loss was 44.9 million yuan, and the loss expanded by 12.63% year-on-year.

Envolizumab (R&D code: KN035) is the only commercialized product of Alphamab Biopharmaceuticals-B. It was approved for conditional marketing by the National Medical Products Administration in 2021 and is suitable for the treatment of adult patients with advanced solid tumors with unresectable or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR). In July 2024, the company's US partner TRACON Pharmaceuticals, Inc. announced that it would terminate further development of Envolizumab in overseas markets because the key clinical trial did not meet the primary endpoint.

Combined with the 2023 financial report disclosed by Corning Oncology Biopharma-B, the pipelines that are still in the key clinical stage include KN046 combined with chemotherapy for 1L squamous NSCLC, KN035 combined with chemotherapy for 1L biliary tract cancer, and KN026 combined with docetaxel for 1L breast cancer and combined with chemotherapy for 2L gastric cancer/gastroesophageal junction cancer (GC/GEJ). Among them, the indication of KN046 for 1L squamous NSCLC is still in the Pre-NDA status.

https://finance.eastmoney.com/a/202502283332780738.html